Barclays Cuts Charles River Laboratories International (NYSE:CRL) Price Target to $166.00

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its target price decreased by stock analysts at Barclays from $205.00 to $166.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an "equal weight" rating on the medical research company's stock. Barclays's price target points to a potential upside of 1.77% from the company's previous close.

A number of other research firms have also recently weighed in on CRL. UBS Group restated a "neutral" rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. TD Cowen increased their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group dropped their price target on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Finally, JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating on the stock in a research note on Monday, February 3rd. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus price target of $195.71.

Charles River Laboratories International Stock Up 0.5 %

Shares of NYSE CRL traded up $0.86 during trading hours on Tuesday, hitting $163.11. The company had a trading volume of 1,215,947 shares, compared to its average volume of 1,060,465. The stock has a market capitalization of $8.34 billion, a P/E ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 1-year low of $150.79 and a 1-year high of $275.00. The firm's 50 day moving average is $172.84 and its 200-day moving average is $188.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 EPS. On average, analysts expect that Charles River Laboratories International will post 9.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Birgit Girshick purchased 1,514 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by company insiders.

Institutional Trading of Charles River Laboratories International

Large investors have recently bought and sold shares of the business. Versant Capital Management Inc boosted its stake in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after buying an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. boosted its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. boosted its stake in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after buying an additional 173 shares in the last quarter. Optiver Holding B.V. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at about $37,000. Finally, GeoWealth Management LLC boosted its stake in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).